Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 30, Issue 5, 2015, Pages 767-772

  Reich, Reuven ^a   Hoffman, Amnon ^a   Suresh, R Rama ^a   Shai, Ofra ^a   Frant, Julia ^a   Maresca, Alfonso ^b   Supuran, Claudiu T ^b   Breuer, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autotaxin; carbamoylphosphonate; carbonic anhydrase; matrix metalloproteinase

Indexed keywords

AUTOTAXIN; CARBAMIC ACID DERIVATIVE; CARBAMOYLPHOSPHONATE; CARBENE; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; ANTINEOPLASTIC AGENT; PHOSPHODIESTERASE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; EXTRACELLULAR SPACE; FEMALE; HALF LIFE TIME; IC50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION CONSTANT; LUNG METASTASIS; MELANOMA METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; ORAL DRUG ADMINISTRATION; SECONDARY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; ORGANOPHOSPHONATES; PHOSPHORIC DIESTER HYDROLASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84940663159     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2014.968146     Document Type: Article

References (29)

1. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524-9.
2. Gijsbers R, Aoki J, Arai H, Bollen M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 2003;538:60-4.
3. Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2006;2:361-70.
4. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277:39436-42.
5. Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009;9:15-23.
6. Albers HM, Ovaa H. Chemical evolution of autotaxin inhibitors. Chem Rev 2012;112:2593-603.
7. Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89: 2-7.
8. Pastorekova S, Zavadova Z, Kostal M, et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620-6.
9. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81.
10. st ed. Boca Raton, NY, London: CRC Press; 2004.
11. Cecchi A, Supuran CT. Fluorescence- and spin-labeled carbonic anhydrase inhibitors. Curr Pharm Des 2008;14:699-707.
12. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-77.
13. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-45.
14. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
15. Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012;55:7875-82.
16. Breuer E, Salomon CJ, Katz Y, et al. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl-and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004;47: 2826-32.
17. Reich R, Katz Y, Hadar R, Breuer E. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentyl-carbamoylphosphonic acid in experimental metastasis and angiogenesis. Clin Cancer Res 2005;11:3925-9.
18. Frant J, Veerendhar A, Chernilovsky T, et al. Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors. ChemMedChem 2011;6: 1471-7.
19. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
20. Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 2009;21:645-53.
21. Madan D, Ferguson CG, Lee WY, et al. Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate. PLoS One 2013;8:e79065.
22. Jahnke W, Henry C. An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 2010;5:770-6.
23. Shinoda H, Adamek G, Felix R, et al. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
24. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005;5:786-95.
25. McIntyre A, Patiar S, Wigfield S, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012;18:3100-11.
26. Stellas D, Patsavoudi E. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med Chem 2012;12:707-17.
27. Lia NG, Shib ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 2009;16: 3805-27.
28. Farkas E, Katz Y, Bhusare S, et al. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 2004;9:307-15.
29. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16:571-639.